Regen Biopharma Financials
Regen Biopharma (RGBP) reported $237K in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny, flat revenue leaves the company operating as a financing-dependent enterprise, with lower losses coming mainly from reduced spending.
With revenue still hovering near$237K , the latest operating loss of-$339K points to spending restraint rather than commercial scale. Financing inflows of$452K also exceeded year-end cash of$70K , showing that even a smaller burn did not make the business internally funded.
The balance sheet is structurally thin: current assets of
A prior year of positive net income never showed up in operating cash flow, which highlights an earnings-quality mismatch between accounting results and the cash engine of the business. The recent losses therefore look less like a sudden break and more like a return to the underlying pattern: modest reported revenue, recurring cash burn, and reliance on outside funding.
Financial Health Signals
Regen Biopharma does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Regen Biopharma scores -141.22, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($168K) relative to total liabilities ($6.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Regen Biopharma passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Regen Biopharma reported a net loss of $1.3M while operations used $384K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Regen Biopharma reported an operating loss of $339K against $158K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Regen Biopharma generated $237K in revenue in fiscal year 2025. That is unchanged from the prior year.
Regen Biopharma reported -$1.3M in net income in fiscal year 2025. This represents a decrease of 90.7% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Regen Biopharma held $70K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
Regen Biopharma invested $12K in research and development in fiscal year 2025. This represents a decrease of 92.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
RGBP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $59K0.0% | $59K0.0% | $59K-0.5% | $59K+0.5% | $59K0.0% | $59K0.0% | $59K-0.5% | $59K |
| R&D Expenses | $0-100.0% | $2K-98.9% | $210K+1691.0% | $12K | $0 | $0 | $0-100.0% | $34K |
| SG&A Expenses | $14K-56.9% | $32K-86.2% | $232K+1206.5% | $18K-42.2% | $31K+130.0% | $13K+0.2% | $13K+134.8% | -$38K |
| Operating Income | $25K+116.0% | -$154K+72.1% | -$552K-348.3% | -$123K-201.9% | -$41K+64.0% | -$113K-84.7% | -$61K+28.1% | -$85K |
| Interest Expense | $30K+10.9% | $27K+3.1% | $27K-69.1% | $86K+248.9% | $25K+10.3% | $22K-11.9% | $25K+26.4% | $20K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | -$638K-164.3% | $992K+202.5% | -$968K-69.1% | -$572K-242.2% | -$167K-764.4% | -$19K+96.2% | -$515K-94.6% | -$265K |
| EPS (Diluted) | $0.00 | $0.00 | -$0.01 | -$0.02 | -$0.01 | $0.00+100.0% | -$0.13 | -$0.06 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
RGBP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $288K+10.5% | $260K+9.8% | $237K-13.7% | $275K+39.5% | $197K+16.1% | $169K-11.5% | $191K+18.8% | $161K |
| Current Assets | $288K+10.5% | $260K+9.8% | $237K-13.7% | $275K+53.3% | $179K+18.0% | $152K-12.6% | $174K+21.2% | $143K |
| Cash & Equivalents | $239-11.8% | $271-94.1% | $5K-93.4% | $70K+3849.7% | $2K0.0% | $2K+1204.4% | $135-81.1% | $716 |
| Accounts Receivable | $287K+10.6% | $260K+11.8% | $232K+13.4% | $205K+15.7% | $177K+18.3% | $150K+22.4% | $122K+28.9% | $95K |
| Total Liabilities | $6.2M+9.7% | $5.6M-17.5% | $6.8M+3.9% | $6.6M+9.0% | $6.0M+2.5% | $5.9M0.0% | $5.9M+9.1% | $5.4M |
| Current Liabilities | $6.2M+9.7% | $5.6M-17.5% | $6.8M+3.9% | $6.6M+9.0% | $6.0M+2.5% | $5.9M0.0% | $5.9M+9.1% | $5.4M |
| Total Equity | -$5.9M-9.7% | -$5.4M+18.5% | -$6.6M-4.6% | -$6.3M-8.0% | -$5.8M-2.1% | -$5.7M-0.3% | -$5.7M-8.8% | -$5.2M |
| Retained Earnings | -$22.3M-2.9% | -$21.7M+4.4% | -$22.7M-4.5% | -$21.7M-2.7% | -$21.1M-0.8% | -$21.0M-0.1% | -$20.9M-2.5% | -$20.4M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
RGBP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$24K+61.9% | -$63K+68.1% | -$198K-23.7% | -$160K-185.8% | -$56K+44.7% | -$101K-52.5% | -$66K+68.0% | -$207K |
| Financing Cash Flow | $24K-59.2% | $59K-55.7% | $133K-41.6% | $228K+307.0% | $56K-45.6% | $103K+56.3% | $66K-55.0% | $146K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
RGBP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.5% | -260.2% | -933.9% | -207.3% | -69.0% | -191.9% | -103.9% | -143.9% |
| Net Margin | -1079.8% | 1679.4% | -1638.6% | -964.3% | -283.2% | -32.8% | -872.6% | -446.2% |
| Return on Assets | -221.8%-603.0pp | 381.2%+789.5pp | -408.2%-199.8pp | -208.4%-123.5pp | -85.0%-73.6pp | -11.4%+257.8pp | -269.3%-104.8pp | -164.5% |
| Current Ratio | 0.050.0x | 0.050.0x | 0.030.0x | 0.040.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.03 |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Regen Biopharma Ranks
Frequently Asked Questions
What is Regen Biopharma's annual revenue?
Regen Biopharma (RGBP) reported $237K in total revenue for fiscal year 2025. That is unchanged from the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Regen Biopharma's revenue growing?
Regen Biopharma (RGBP) revenue was essentially unchanged year-over-year, at $237K in fiscal year 2025 against $237K the year before.
Is Regen Biopharma profitable?
No, Regen Biopharma (RGBP) reported a net income of -$1.3M in fiscal year 2025.
What is Regen Biopharma's operating cash flow?
Regen Biopharma (RGBP) recorded an outflow of $384K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Regen Biopharma's total assets?
Regen Biopharma (RGBP) had $275K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Regen Biopharma spend on research and development?
Regen Biopharma (RGBP) invested $12K in research and development during fiscal year 2025.
What is Regen Biopharma's current ratio?
Regen Biopharma (RGBP) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Regen Biopharma's return on assets (ROA)?
Regen Biopharma (RGBP) had a return on assets of -464.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Regen Biopharma's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Regen Biopharma (RGBP) held $70K in cash, cash equivalents and investments, and reported an operating cash outflow of $384K over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Regen Biopharma's debt-to-equity ratio negative or not reported?
Regen Biopharma (RGBP) has negative shareholder equity of -$6.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Regen Biopharma's Altman Z-Score?
Regen Biopharma (RGBP) has an Altman Z-Score of -141.22, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Regen Biopharma's Piotroski F-Score?
Regen Biopharma (RGBP) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regen Biopharma's earnings high quality?
Regen Biopharma (RGBP) reported a net loss of $1.3M while operations used $384K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Regen Biopharma cover its interest payments?
Regen Biopharma (RGBP) reported an operating loss of $339K against $158K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.